ABEONA THERAPEUTICS INC. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
ABEONA THERAPEUTICS INC. (ABEO) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-30.
Discontinued › Notes
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2017-03-30
- ABEONA THERAPEUTICS INC. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2016-12-31 was $0.00.
- ABEONA THERAPEUTICS INC. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2016-09-30 was $0.00.
- ABEONA THERAPEUTICS INC. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2015-12-31 was $0.00.
- ABEONA THERAPEUTICS INC. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2015-09-30 was $0.00.
- ABEONA THERAPEUTICS INC. business combination, consideration transferred, equity interests issued and issuable for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- ABEONA THERAPEUTICS INC. business combination, consideration transferred, equity interests issued and issuable for fiscal 2015 was $31.76M.
- ABEONA THERAPEUTICS INC. business combination, consideration transferred, equity interests issued and issuable for fiscal 2014 was $0.00.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 3 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 6 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 9 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $0.00 derived: sum of 2 quarters · filed 2017-03-30 | $0.00 10-K · filed 2017-03-30 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $0.00 10-Q · filed 2016-11-14 | ||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-15 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $0.00 derived: sum of 2 quarters · filed 2017-03-30 | $31.76M 10-K · filed 2017-03-30 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $31.76M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $31.76M 10-Q · filed 2016-08-15 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $0.00 10-K · filed 2016-03-30 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | $0.00 10-Q · filed 2015-11-16 | ||
| 2014-06-30 | $0.00 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |